Macrophage activation syndrome is a potentially fatal clinical syndrome caused by an excessive activation and proliferation of macrophages and T cells, leading to an exaggerated inflammatory reaction. It is well known that it can complicate the course of different conditions, especially autoimmune, lympho-proliferative, infectious diseases and drugs. Many infective pathogens can trigger the syndrome but the association with malaria has rarely been described, especially in children. We report a child with severe malaria complicated by MAS, in whom the clinical appearance of this syndrome could be considered as worsening of malaria itself. Furthermore, the use of steroids as first choice drugs in this complication, but arguable in malaria, has been highlighted. Clinicians should be aware of this syndrome when malaria does not respond to conventional therapy, since early diagnosis and prompt treatment may dramatically reduce the mortality associated with this condition.
Macrophage activation syndrome (MAS) is a severe clinical syndrome caused by an excessive activation and proliferation of well differentiated macrophages and T cells leading to an exaggerated inflammatory reaction (1) . Because of its lifethreatening potential, MAS requires prompt recognition and intravenous corticosteroid administration (l). This condition usually occurs in various autoimmune disorders and represents a potentially fatal complication (2) . However, it is known to occur in a heterogeneous group of diseases including malignancy, immunodeficiency, hematological and infectious diseases. Malaria has been very rarely described as complicated by MAS; few cases of MAS during malaria have been reported in childhood (3, 4) . Therefore, we report the case of a 6-year-old boy who developed MAS during malaria.
Case report
A previously healthy 6-year-old boy presented with persistent high fever, headache, and vomiting on returning from a three-month-stay in Togo. The mother reported that he had taken malaria prophylaxis with mefloquine for the first 45 days of his stay. On physical examination he manifested hepatomegaly and subicterus. He was febrile, irritable, and drowsy with stiffness of the trunk. Nevertheless, neurologic exam was completely negative, so that a central nervous system involvement was excluded. His blood tests revealed high C-reactive protein (CRP; 196.7 mg/L), thrombocytopenia (PLT; 70 xl0 9/L)), hypertransaminasemia (AST: 218 lUlL, ALT: 114 lUlL), high bilirubin (8.4 mgldL), high lactic dehydrogenase (LOB; 1,167lUlL), hyperferritinemia (4,030 ng/mL), hypertriglyceridemia (580 mg/dL) and hyponatremia (130 mEq/L) (Table I) . Blood culture, molecular detection of common bacteria DNA through polymerase chain reaction (PCR) on blood samples, and antibodies against hepatitis B and C viruses and human immunodeficiency virus (HIV) were negative. The patient had normal values of circulating lymphocytes, and humoral immunity was also normal. Abdomen ultrasonography, ophthalmologic and cardiac evaluations were also normal. His peripheral blood smears showed ring form Plasmodium falciparum (Pf) with a parasite index of3.8%. The child was treated with intravenous quinine and ceftriaxone. Ten hours after the beginning The child was on pulse methylprednisolone (400 mg once a day) for 2 days followed by oral prednisone (20 mg twice/day). Two days later, his clinical conditions improved and the fever disappeared. All the hematological abnormalities normalized and his peripheral blood smear revealed the absence of Pf All laboratory data either at onset or during the course of disease are summarized in Table I . Oral prednisone was tapered and stopped within 2 weeks. The patient was subsequently discharged and has been seen twice in last 6 months and is doing well.
DISCUSSION
MAS is a potentially fatal condition associated with excessive activation and expansion of macrophages and T cells, leading to an exaggerated inflammatory reaction, and resulting in liver dysfunction, encephalopathy, pancytopenia and disseminated intravascular coagulation (1, 6) . MAS is very similar to a group of histiocytic disorders known as hemophagocytic lymphohistiocytosis (HLH). This term includes a wide spectrum of diseases characterized by abnormal accumulations of well differentiated macrophages. HLH includes the autosomal recessive genetic disorders known as familial HLH (FHLH) and the acquired form known as reactive HLH (RHLH) (2) . Reactive HLH can be secondary to several infectious agents, autoimmune diseases, malignancies and medications. Hence, it is thought that RHLH and MAS may represent the same entity. MAS was first described in children with systemic juvenile idiopathic arthritis and then in many other autoimmune conditions, such as systemic lupus erythematosus, dermatomiositis, ankylosing spondylitis, Kawasaki disease, and inflammatory bowel disease (2) . Moreover MAS has been related to a variety of viral, bacterial, fungal, and parasitic infections. Among the viruses, Epstein Barr virus is the most common triggering agent; other viruses include all herpes viruses, HIV, influenza virus, parvovirus, hepatitis virus, adenovirus and enteroviruses. More rarely, MAS has been described in the course of measles, mumps, rubella, and dengue. The syndrome has also been described during Mycobacteria infections and after adjuvant intravesical BCG therapy and BCG vaccination. Campylobacter spp, Fusobacterium spp, mycoplasma, chlamydia, legionella, salmonella, rickettsia, brucella, ehrlichia, and borrelia, as well as other bacterial infections, have been identified in patients with hemophagocytic syndrome. MAS can either be associated with yeast or mould infections in immunocompromised patients. Many parasitic diseases, such as toxoplasmosis, babesiosis, and strongyloidias, can be complicated by MAS (6, 7) . The association between MAS and malaria has been occasionally found in adults (8) (9) . Whereas, only two cases are reported in previously healthy adolescents affected with malaria and complicated by hemophagocytosis (3, 4) . Moreover, malaria has been described as triggering a hemophagocytic syndrome in a boy with Langerhans cell histiocytosis (10) . The pathogenesis of MAS during a parasitic infection may be complex. Macrophages are known to be implicated in the resistance to parasites, but other mechanisms may be involved. Leukocyte activation by malarial pigments accumulated in the reticuloendotelial system is one of the possible mechanism suggested (11). It is possible that some patients have predisposing factors to an immune dysregulation so that macrophages, stimulated by the pathogen, are abnormally activated and cause an exaggerated inflammatory reaction. The main clinical manifestations of MAS include persistent fever, skin rash, hepatosplenomegaly, and lymphadenopathy (I). Neurological abnormalities, ranging from mental status change to seizures or coma, renal function impairment and pulmonary infiltrates can also be present (1) . The typical laboratory abnormalities consist of severe cytopenia, liver dysfunction, coagulopathy (altered prothrombin time, and partial thromboplastin time, low fibrinogen, high fibrin split products and low platelet counts) consistent with DIC, and hypertriglyceridemia. Serum ferritin level> 10,000 ng/mL is an important diagnostic clue of MAS (6) . A sudden drop in ESR, secondary to decreased fibrinogen levels and liver dysfunction, combined with persistently high CRP is the first sign of impending MAS (6) .
Pancytopenia is caused by increased destruction of the cells by phagocytosis and/or consumption. The diagnosis of MAS should be made according to the revised diagnostic criteria for HLH (12) and confirmed by the demonstration ofhemophagocytosis in samples from bone marrow, lymph nodes or liver (I, 2). However, as hemophagocytosis may be not always found, the biopsy should be performed only in doubtful cases (6) .
High-dose glucocorticosteroids are the firstline treatment for MAS. In unresponsive patients cyclosporine A, etoposide with cyclophosphamide and antithymocyte globulin can be used as an alternative treatment (3). Etanercept and anakinra have also been tried, although MAS has been reported in some SJlA patients treated with these drugs.
In our patient, MAS symptoms developed almost simultaneously with the malaria attack, so that fever, anemia, hepatosplenomegaly, thrombocytopenia and liver dysfunction had been initially attributed only to the parasitic infection. Thus, the first line treatment for malaria (quinine) had been applied. The failed clinical and laboratory responses firstly directed us to a form of drug-resistant malaria. Artesunate was therefore introduced. Nevertheless, the patient's clinical condition further deteriorated. Moreover, the occurrence of hypofibrinogenemia, together with ever-increasing values of triglyceridemia, ferritinemia, and CRP led us to consider the beginning of MAS. Other laboratory abnormalities, usually observed in MAS, such as hyponatremia and low ESR, were still found in our patient.
As our case fulfilled five of the diagnostic criteria (fever, splenomegaly, cytopenia, hypertriglyceridemia, hyperferritinemia), bone marrow examination, which is supportive but not essential for the diagnosis, was not performed. Our patient's clinical outcome is similar to that already reported in an Indian adolescent (3) . In our case either the initial signs or the complete development of MAS were slightly milder than those reported in the Indian boy (3): our patient did not present any rash or central nervous system and conjunctival involvement, and hyponatremia was transient and moderate. Moreover, in our case, after starting steroid treatment, the clinical conditions promptly improved, compared to the Indian case in whom the disease was more aggressive (3). Our early diagnosis of MAS and prompt steroid treatment favored the rapid MAS resolution. Corticosteroids are in fact the drugs of choice, intravenously, particularly pulse therapy with methylprednisolone in MAS. However, in our case primarily affected by malaria, the use of steroids had been carefully evaluated. In fact, the choice of steroid therapy during a bout of malaria could be arguable, because it may decrease the host's response against plasmodium. It was demonstrated that chronic steroid administration suppresses the host's immunity, without any suppressive effects on the parasite's development and maturation, and it increases the maturation of Plasmodium in the animal model. On the other hand, steroids, used in the past to reduce inflammation in cerebral malaria, are not recommended at present by international guidelines for malaria since evidence oftheir efficacy is lacking. Therefore, only after having made certain diagnosis of MAS, steroids should be introduced. In conclusion, the diagnosis of MAS as a complication of an infectious disease could be difficult, because some of its symptoms can be initially explained with the infection itself. Interestingly, malarial parasites can cause some clinical and hematological features very similar to clinical findings of MAS, so that clinicians should be aware of this association. In cases with malaria not responding to conventional therapy, a drug-resistant infection should be firstly suspected, and the therapy should be shifted to an alternative drug. Subsequently, if the patient's clinical conditions do not improve even with secondline treatment, the occurrence of MAS should be considered and typical hematological abnormalities should be looked for to confirm the diagnosis.
Early diagnosis and prompt steroidal treatment may dramatically reduce the mortality associated with this condition.
